Named Patient or Compassionate Use for Treatment Use of ATB200/AT2221 for Patients With Pompe Disease

Amicus Therapeutics0 个研究点开始时间: 2019年3月7日最近更新: 2025年9月15日

适应症

试验速览

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

This program is being offered on a patient by patient basis and will require company, IRB/IEC and single patient IND approval.

•Subject must have a diagnosis of Pompe disease based on documentation of one of the following:
•deficiency of GAA enzyme
•GAA genotyping
•Patient does not currently qualify for an Amicus sponsored on-going clinical trial or is declining on currently approved ERT (e.g. Myozyme)
•The patient must be willing to receive treatment with ATB200/AT2221 via this program, which includes signing an authorization form for sharing clinical data with Amicus Therapeutics, and its agent Early Access Care LLC.

•Patient, whether male or female, is planning to conceive a child during the treatment program.
•Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221
•Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with or adversely impact protocol requirements.
•Patient has received any gene therapy at any time.
•Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb, or Volibo)

发起方

申办方类型

Industry

责任方

Sponsor